<\/p>\n
<\/p>\n
With revenue up 11.7% at constant exchange rates in the third quarter of 2025 to \u20ac6.867 billion<\/strong>, this performance, the strongest since the group was created from the merger between Essilor and Luxottica in 2018<\/strong>, illustrates the relevance of its strategy focused on innovation, diversification of its brand portfolio, and strengthening of its visual health ecosystem.<\/p>\n <\/p>\n In addition, for the first nine months of the year, the group’s revenues reached \u20ac20.891 billion<\/strong>, up +8.8% at constant exchange rates<\/strong>.<\/p>\n <\/p>\n <\/p>\n A real driver of growth this quarter, the artificial intelligence eyewear<\/strong> category<\/strong> is expanding rapidly. The new Ray-Ban Meta Gen 2, Oakley Meta HSTN<\/strong>, and Meta Ray-Ban Display <\/strong>models, launched in September in partnership with Meta, have been a huge hit with consumers. These smart glasses are now positioned as a strategic category, contributing both to the group’s innovative image and to the expansion of its audience, particularly among younger generations.<\/p>\n <\/p>\n Beyond this phenomenon, the optical and sunglass categories<\/strong> are also growing at a solid rate of +5% <\/strong>at constant exchange rates and on a like-for-like basis.<\/p>\n <\/p>\n In the Professional Solutions segment<\/strong>, which includes sales of products to opticians, revenue reached \u20ac3.223 billion, up 11.9%. <\/strong>Ray-Ban, Nikon, and Shamir were among the best-performing brands.<\/p>\n <\/p>\n The Direct to Consumer segment<\/strong>, which includes store networks and online sales, recorded an increase of +11.6%, for a total of \u20ac3.644 billion<\/strong>. Same-store sales grew by more than 7%, particularly in North American and European stores.<\/p>\n <\/p>\n <\/p>\n In the third quarter, North America<\/strong> emerged as a growth driver, with a 12.1% <\/strong>increase at constant exchange rates and revenue of nearly \u20ac3 billion (\u20ac2.996 billion<\/strong>). Sales of connected glasses and the consolidation of the Supreme<\/strong> brand contributed significantly to this growth.<\/p>\n <\/p>\n In Europe, the Middle East, and Africa (EMEA)<\/strong>, growth was even stronger, reaching +12.7%<\/strong>, with revenue of \u20ac2.694 billion. Varilux Physio Extensee, Nikon Z Suite<\/strong>, and Transitions Gen S<\/strong> lenses performed extremely well, while AI-enabled eyewear and licensed brands such as Miu Miu, Chanel<\/strong>, and Oakley<\/strong> supported growth in frames.<\/p>\n <\/p>\n The Asia-Pacific region<\/strong> posted revenue of \u20ac822 million<\/strong>, up 10.5%<\/strong> at constant exchange rates. Greater China confirmed its rebound, driven by Nikon <\/strong>and Kodak DOT<\/strong> lenses, while Australia and South Korea also showed strong momentum for the Oakley<\/strong> brand.<\/p>\n <\/p>\n Finally, in Latin America<\/strong>, growth stood at +5.2%, <\/strong>slowed by a slight downturn in Brazil and Mexico after two particularly strong quarters. Revenue for this region was \u20ac355 million<\/strong>, boosted nonetheless by solid performances in Argentina and Colombia.<\/p>\n <\/p>\n <\/p>\n For Francesco Milleri<\/strong>, Chairman and CEO, and Paul du Saillant<\/strong>, Deputy CEO, these results validate the group’s strategy : “Today we are reporting our best quarter since the Group was created. With remarkable contributions from EMEA and North America, and thanks to the rise of wearables and the strong momentum of visual health and sunglasses, these results attest to the effectiveness of our strategy, carried out with determination and excellence. As we enter the fourth quarter, we are showing strong momentum and a clear ambition to drive sustainable transformation, defining a future where innovation, science and human potential progress together.”<\/em><\/p>\n <\/p>\n EssilorLuxottica is thus continuing its transformation into a global player in visual health, combining technological innovation and treatment. The launch of the new Stellest<\/strong> lens on the US market marks a major milestone in the fight against childhood myopia, a global public health issue.<\/p>\n <\/p>\n At the same time, the group is strengthening its foothold in medtech with two major transactions : the completion of the acquisition of the British network of Optegra<\/strong> eye clinics, now consolidated since October 1, and the announcement of the acquisition of Swiss start-up RetinAI<\/strong>, which specializes in medical image analysis using artificial intelligence.<\/p>\n <\/p>\nAI glasses as a growth driver<\/h2>\n
Balanced global performance<\/h2>\n
Focus on med-tech and integrated visual health<\/h2>\n